Epitopes described in "RTL therapy for multiple sclerosis: a Phase I clinical study."

Reference
Article Authors:Halina Offner; Sushmita Sinha; Gregory G Burrows; Adolph J Ferro; Arthur A Vandenbark
Article Title:RTL therapy for multiple sclerosis: a Phase I clinical study.
Reference Detail
Reference ID:1021508
Abstract:A human recombinant T cell receptor ligand (RTL1000) consisting of DR2 1 and 1 domains linked covalently to MOG-35-55 peptide can reverse clinical and histological signs of experimental autoimmune encephalomyelitis (EAE), and was evaluated for safety in a Phase 1 randomized, placebo-controlled, escalating dose study in 34 subjects with multiple sclerosis (MS). RTL1000 was safe and well tolerated at a dose of ≤60 mg that is well within the effective dose range for EAE and did not cause worsening of MS disease at doses ≤200 mg. RTL1000 represents a novel approach for the treatment of MS that promises potent immunoregulation and CNS repair without global immunosuppression.
Date:2011
Reference Type:Literature
PubMed ID:20965577
Journal:J Neuroimmunol
Journal Volume:231
Article Pages:7-14
Journal ISSN:0165-5728
Article Chemical List:RTL1000 protein;Recombinant Fusion Proteins;Recombinant Proteins
Article MeSH List:Animals; Dose-Response Relationship, Immunologic; Double-Blind Method; Encephalomyelitis, Autoimmune, Experimental(drug therapy; immunology); Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Multiple Sclerosis(drug therapy; immunology); Protein Structure, Secondary; Rats; Rats, Inbred Lew; Recombinant Fusion Proteins(chemistry; therapeutic use); Recombinant Proteins(chemistry; therapeutic use)
Curation Last Updated:2014-10-03 22:17:35